BioCentury
ARTICLE | Company News

Arch Biopartners, Emory University, University of Colorado deal

September 12, 2011 7:00 AM UTC

Arch identified GH501a as its lead compound to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. GH501a is in preclinical development at the universities. Under a 2010 deal, Arch's Color...